Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study
在3b期SOLAR研究中,与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺相比,卡博特韦+利匹韦林长效维持治疗12个月后,患者报告结局有所改善。
期刊:Aids and Behavior
影响因子:2.4
doi:10.1007/s10461-024-04490-0
Mussini, Cristina; Cazanave, Charles; Adachi, Eisuke; Eu, Beng; Alonso, Marta Montero; Crofoot, Gordon; Chounta, Vasiliki; Kolobova, Irina; Sutton, Kenneth; Sutherland-Phillips, Denise; Urbaityte, Rimgaile; Ehmann, Alice; Scherzer, Jenny; de Los Rios, Patricia; D'Amico, Ronald; Spreen, William; van Wyk, Jean